


## IN ORDER OF APPEARANCE

**Harry P. Selker, MD, MSPH**

Dean and Principal Investigator, Tufts CTSI; Executive Director, Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts Medical Center; Professor of Medicine and Clinical and Translational Science, Tufts University School of Medicine



As Dean of Tufts Clinical and Translational Science Institute (CTSI), Dr. Selker provides leadership for programs and infrastructure that support clinical and translational research at the Tufts University schools and affiliated hospitals, and other academic, community-based, and industry Tufts CTSI partners. He practices medicine at Tufts MC.

Dr. Selker's research focuses on the development of treatment strategies aimed at improving medical care. He is known for his studies of the factors influencing emergency cardiac care and for development of "clinical predictive instruments," mathematical models that are used as decision aids. They provide emergency physicians and paramedics with predictions for their patients' likely cardiac diagnoses and outcomes for real-time use in clinical care. This has included conduct of multiple large national clinical effectiveness trials that have demonstrated better treatment and clinical outcomes for patients with acute coronary syndromes. Additionally, Dr. Selker has done research to advance clinical study design, execution, issues around informed consent, data analysis, mathematical predictive modeling of medical outcomes, and comparative effectiveness research.

Dr. Selker has contributed to health services and health policy research, with a focus on translational research that impacts public health. He has provided advice about health care delivery and medical research to policymakers, including the House and Senate authors of the Affordable Care Act. Dr. Selker has served as President of the Society of General Internal Medicine, the Society for Clinical and Translational Science, the Association for Clinical Research Training, and the Association for Clinical and Translational Science, and is currently Chair of the Clinical Research Forum.

**Michael G. Kurilla, MD, PhD**

Director, Division of Clinical Innovation, NCATS



Dr. Kurilla is the director of the Division of Clinical Innovation at NCATS. In this capacity, he oversees the Clinical and Translational Science Awards (CTSA) Program, which supports innovative solutions to advance the efficiency, quality and impact of translational science, with the ultimate goal of getting more treatments to more patients more quickly. Prior to joining NCATS, Dr. Kurilla served as the director of the Office of Biodefense Research Resources and Translational Research within the National Institute of Allergy and Infectious Diseases (NIAID), where he focused on translational efforts toward infectious disease product development, including vaccines, therapeutics and diagnostics, with emphasis on biodefense and emerging infectious disease threats. Prior to joining NIAID in 2003, Dr. Kurilla was an associate director for infectious diseases at Wyeth. He also worked in antimicrobials at DuPont and on clinical microbiology and molecular pathology at the University of Virginia Health Sciences Center. Dr. Kurilla received his MD and his PhD in microbiology and immunology from Duke University. He was a postdoctoral research fellow at Harvard Medical School and completed a residency in pathology at Brigham and Women's Hospital. He received a BS in chemistry from the California Institute of Technology.

**Robert M. Califf, MD, MACC**

Commissioner of Food and Drugs, FDA



Dr. Califf is Commissioner of Food and Drugs. President Joe Biden nominated Dr. Califf to head the U.S. Food and Drug Administration and Dr. Califf was sworn in on February 17, 2022. Previously, Dr. Califf served as Commissioner of Food and Drugs from February 2016 to January 2017. As the top official of the FDA, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health. Dr. Califf served as the FDA's Deputy Commissioner for Medical Products and Tobacco from February 2015 until his first appointment as Commissioner in February 2016.

Prior to rejoining the FDA, Dr. Califf was head of medical strategy and Senior Advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries, Verily Life Sciences and Google Health. He joined Alphabet in 2019, after serving as a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature. Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.

**John W. Jackson, ScD**

Associate Professor, Johns Hopkins University



Dr. Jackson is an Associate Professor in the Departments of Epidemiology, Biostatistics, and Mental Health at the Johns Hopkins Bloomberg School of Public Health, and core faculty in the Johns Hopkins Center for Health Equity, Center for Health Disparities Solutions, and Center for Drug Safety and Effectiveness. His research primarily focuses on developing methodological tools for translational health equity research. This includes methods for the rigorous measurement of health disparities, methods to identify high leverage targets and strategies for interventions that address health disparities, as well as methods to evaluate effects of interventions and policies, with current applications in healthcare and clinical prognosis. For his work in these areas, Dr. Jackson was awarded the 2022 NIH Matilda White Riley Behavioral and Social Sciences Honors Award from the NIH Office of Behavioral and Social Science Research. Dr. Jackson's work has been funded by a K01 award from the National Heart, Lung, and Blood Institute as well as research funding from Johns Hopkins University. He is a member of the editorial board of *Epidemiology* as well as *Sociological Methods & Research*.

**Amanda F. Petrik, PhD**

Investigator, Kaiser Permanente Center for Health Research (CHR)



Dr. Petrik is an early-career investigator and health services researcher with extensive training in social and health systems and policy. Dr. Petrik has more than 20 years of experience conducting research and over a decade implementing and evaluating cancer prevention programs in diverse practice settings, including in community clinics. Her research now focuses on the use of predictive analytics in cancer prevention. Dr. Petrik joined the center for Health Research at Kaiser Permanente 2001. In 2021, she earned her PhD in health systems and policy from the OHSU-PSU School of Public Health in Portland. Her dissertation was on developing a colorectal cancer screening risk-prediction model for population health management. She then received a career development award in learning health systems science through the Agency for Healthcare Research and Quality (AHRQ). Her project involves the use of predictive analytics to identify patients at low risk of developing high-risk adenomas or colorectal cancer after a baseline colonoscopy. Dr. Petrik is also working on proposals to implement a multilevel intervention to increase human papillomavirus (HPV) vaccination in school-based health centers, to implement a self-collected HPV testing program, and to reassess colonoscopy surveillance.

**Marzyeh Ghassemi, MSc, PhD**

Assistant Professor, MIT



Dr. Ghassemi is an Assistant Professor at MIT in Electrical Engineering and Computer Science (EECS) and Institute for Medical Engineering & Science (IMES), and a Vector Institute faculty member holding a Canadian CIFAR AI Chair and Canada Research Chair. She holds MIT affiliations with the Jameel Clinic and CSAIL. Dr. Ghassemi holds a Herman L. F. von Helmholtz Career Development Professorship, and was named a CIFAR Azrieli Global Scholar and one of MIT Tech Review’s 35 Innovators Under 35. Previously, she was a Visiting Researcher with Alphabet’s Verily and an Assistant Professor at University of Toronto. Prior to her PhD in Computer Science at MIT, she received a MSc. degree in biomedical engineering from Oxford University as a Marshall Scholar, and B.S. degrees in computer science and electrical engineering as a Goldwater Scholar at New Mexico State University. Dr. Ghassemi has previously served as a NeurIPS Workshop Co-Chair and General Chair for the ACM Conference on Health, Inference and Learning (CHIL). She also founded the non-profit Association for Health Learning and Inference. Dr. Ghassemi has published across computer science and clinical venues, including NeurIPS, KDD, AAAI, MLHC, JAMIA, JMIR, JMLR, AMIA-CRI, Nature Medicine, Nature Translational Psychiatry, and Critical Care. Her work has been featured in popular press such as Fortune, MIT News, NVIDIA, and The Huffington Post.

**Ayanna K. Thomas, PhD**

Professor and Dean of Research for Arts and Sciences, Tufts University School of Arts and Sciences



Dr. Thomas is the Dean of Research in Arts and Sciences and Professor of Psychology at Tufts University. Dr. Thomas investigates interactions between memory and metamemory to better understand the role metamemory plays in memory acquisition, distortion, and access. In her role as Dean, she serves as primary advisor to the school's Dean and works to support department chairs and faculty in research matters. In addition, Ayanna is a key liaison between the Office of the Vice

Provost of Research and A&S faculty in promoting and facilitating the research mission of the school and the university. She manages the school’s Research Administration team and sits on the University-wide Research Council. She also oversees the Visiting and Early Research Scholars' Experience (VERSE) Program.

**Aviva Must, PhD**

Director, Small Grants to Advance Translational Science Program (S-GATS), Tufts CTSI, Professor of Medicine, Tufts University School of Medicine



Dr. Must is the Morton A. Madoff Professor of Public Health and Chair of the Department of Public Health and Community Medicine at Tufts School of Medicine. Dr. Must is a nutritional epidemiologist who has worked in population-based obesity research since 1988. She focuses on the epidemiology of obesity across the lifespan with a particular interest in physical and psychosocial health consequences during adolescence and in vulnerable populations. Additional research foci include the development of valid survey measures and surveillance systems for pediatric obesity and proximal modifiable behaviors (nutrition, physical activity, sedentary behavior). Recent efforts have been directed towards developing the descriptive epidemiology and health promotion for children with developmental disabilities. Dr. Must directs the Clinical and Community Research Core of the Boston Nutrition Obesity Research Center, a cross-institution NIH-funded Obesity Center and is co-director of the Healthy Weight Research Network for Children with Autism Spectrum Disorders and Developmental Disabilities, funded by the Maternal and Child Health Bureau of HRSA, USDHHS.

**Eric Anderson, PhD**

Faculty Scientist I, MaineHealth Institute for Research




Dr. Anderson is an early career investigator at the Center Interdisciplinary Population and Health Research at the MaineHealth Institute for Research. He completed a PhD in experimental psychology at Northeastern University with a focus on affective science. His current research explores psychosocial factors in medical decision making and access to care. Recent projects have examined how income and geographical location influence patients’ access to cutting edge cancer care. He is particularly interested in improving outcomes for socially disadvantaged individuals

**Interactive Research Studio Discussants**

**Susan Asci**

Financial Writer and Patient Advocate



Ms. Asci is a 22-year survivor of inflammatory breast cancer (IBC), a rare and aggressive form of breast cancer. The symptoms of IBC are atypical and difficult to diagnose. The disease is at an advanced stage upon presentation. Survival rates are much lower than other forms of breast cancer. Susan has been a patient and research advocate for 22 years. She has founded several research initiatives and founded the first and longest running support network for patients. She founded IBC New England, a nonprofit charitable educational organization providing information and resources for patients. Her group successfully advocated for the passage of a permanent Inflammatory Breast Cancer Awareness Day in Massachusetts, the first in the northeast. The bill passed and Governor Charlie Baker signed it into law in January 2023. The day is the

second Tuesday of every October. She continues to contribute to advancing research with Tufts CTSI and other area cancer centers, and is a voice for those battling rare diseases. These activities are part of what she considers her volunteer life. Susan is a full-time financial writer and editor.

**Denise Daudelin, RN, MPH**

**Director, Research Process Improvement, Tufts CTSI, Assistant Professor, Tufts University School of Medicine**

Ms. Daudelin is a research scientist with experience in using Improvement Science methods to improve research processes. She co-leads the Dissemination and Implementation (D&I) Science Special Interest Group and provides D&I consultations through the D&I Core. Ms. Daudelin leads Tufts CTSI’s Patient-Centered Learning Health System Initiative and was recently the Project Director for the NIH sponsored Common Metrics Initiative to implement and improve quality and performance measures at 64 Clinical and Translational Science Award research organizations across the nation. She has over 25 years of experience in quality improvement leadership, consulting, teaching and research. Ms. Daudelin’s clinical experience includes adult medical and surgical care. Before joining the Center for Cardiovascular Health Services Research, Ms. Daudelin was Director of Outcomes Analysis and Quality Improvement at Tufts Medical Center, where she developed and implemented operational QI and patient safety programs, co-developed QI and Resource Utilization software, and worked with clinicians to evaluate incidences and causes of medical errors.



**Nadine Linendoll, PhD, MDiv, GNP**

**Nurse Practitioner; Assistant Professor, Tufts University School of Medicine**

Dr. Linendoll is an Assistant Professor of Medicine at Tufts University School of Medicine with more than 25 years of experience, first as a bedside nurse and then as oncology nurse practitioner. She currently cares for patients in the Reid R. Sacco Adolescent and Young Adult Cancer Program. Prior to seeing patients in clinic, Dr. Linendoll prepares survivorship care plans (including a cumulative treatment summary and a long term follow-up care plan) and oversees their complex care coordination, which spans throughout the greater New England area. Dr. Linendoll is also committed to increasing knowledge and academic scholarship in survivorship-related research, which she conducts through her appointment within the Institute for Clinical Research and Health Policy Studies (Center for Health Solutions). She is currently interested in the financial impacts of cancer and is the lead financial navigator in a multi-site study to explore the role of financial navigation in alleviating financial distress among young adults with a history of blood cancer. This “all-remote” study screened more than 350 AYA survivors of blood cancer from 18 states with serial follow up for 6 months.



**Susan Parsons, MD, MRP**

**Professor of Medicine, Tufts University School of Medicine, Director, Center for Health Solutions, Institute for Clinical Research and Health Policy Studies (ICRHPS)**

Dr. Parsons is a Professor of Medicine and Pediatrics at Tufts University School of Medicine and Medical Director of the Reid R. Sacco AYA Cancer Program at Tufts Medical Center. Her research has focused on strategies to improve the patient’s experience with healthcare, reduce regimen-related toxicity, and optimize functioning. Nationally, she serves as a member of the



Children’s Oncology Group’s (COG) Steering Committees for AYA Oncology and Hodgkin Lymphoma (HL), and as a study team member of several frontline clinical trials in which patient- reported outcomes (PRO) have been embedded. In the recently completed high risk HL pediatric study (AHOD 1331), she led pre-planned studies on chemotherapy-induced peripheral neuropathy, health-related quality of life, and cost effectiveness analysis. In the recently accrued cross-network clinical trial comparing two novel agents in the treatment of advanced stage HL (S1826), Dr. Parsons also serves as the PRO chair. In 2019 Dr. Parsons was appointed scientific lead and chair of cancer care delivery research (CCDR) for COG and has served as a member of the NCI’s Scientific Steering Committee for CCDR for eight years. Within her own research, she is co-founder of the HoLISTIC Consortium (Hodgkin Lymphoma International Study for Individual Care) with the goal of developing clinical decision tools to enhance patient-provider communication on treatment trade-offs in HL. She also leads a multi-institutional study on financial toxicity among blood cancer survivors, examining the role of a financial navigator to mitigate financial distress.

**Fengqing Wang**

Research Assistant, Institute for Clinical Research and Health Policy Studies (ICRHPS)

Ms. Wang is a research assistant within the Institute for Clinical Research and Health Policy Studies (ICRHPS) and a patient navigator at Tufts Medical Center Cancer Center. Ms. Wang has an undergraduate degree in psychology from Endicott College. Since 2015, she has worked with Dr. Parsons on several cancer care delivery research projects. As a patient navigator, she largely serves the Chinese-speaking patients within the cancer center, as well as those vulnerable on the basis of socio-economic status. She has been celebrated and recognized by the Tufts Medical Center for her sensitive insights, meticulous work style, and strong community advocacy. She is a well-sought after community research team member, clinical research team member, and patient navigator.



**Daniel E. Weiner, MD, MS**

Lead Navigator, Tufts CTSI, Professor of Medicine, Tufts University School of Medicine

Dr. Weiner is a Lead Navigator at Tufts CTSI, a nephrologist at Tufts Medical Center, and Associate Professor of Medicine at Tufts University School of Medicine. He is a graduate of Tufts University (LA94) and Tufts University School of Medicine (M98), before completing a Master’s degree program in clinical care research at the Graduate School of Biomedical Sciences (S04). His research interests focus on the intersection of cardiovascular disease and kidney disease. He is the Editor-in-Chief of the National Kidney Foundation’s newest journal, Kidney Medicine, and the co-Editor-in-Chief of the Primer on Kidney Diseases. He is the Medical Director of Clinical Research for Dialysis Clinic, Inc., a national not-for-profit provider of kidney care. He has more than 250 publications, spanning kidney disease, dialysis, health economics and hypertension research, including cohort studies and clinical trials.

